Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 9/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062623 | 0.87 | PEPD (0.80) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL1322717 | 0.78 | PEPD (1.00) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL5536751 | 0.78 | PEPD (0.67) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL6879129 | 0.78 | MAPT (0.70) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL449122 | 0.76 | ALDH1A1 (0.60) | ALDH1A1NPC1MAPTGAAKIF11 | |
| SCHEMBL348736 | 0.76 | F2 (0.42) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL8698243 | 0.76 | PEPD (0.46) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL2235161 | 0.76 | PEPD (0.64) | PEPDALDH1A1NPC1MAPTGAA | |
| SCHEMBL95420 | 0.76 | SMN1; SMN2 (0.67) | ALDH1A1NPC1MAPTGAAMEN1 | |
| SCHEMBL8379303 | 0.76 | PEPD (0.64) | PEPDALDH1A1NPC1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-0738715-B1 | Arylalkyl-pyridazinones | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6399611-B1 | 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0723962-B1 | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| US-6025354-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-15 | — | — | US | disclosed |
| US-5747489-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | PEPD 625/4885ALDH1A1 257/4885NPC1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.